On March 20, 2018 Johnson & Johnson (NYSE: JNJ) reported that it will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 17, to review first-quarter results. Dominic Caruso, Executive Vice President, Chief Financial Officer; Joaquin Duato, Executive Vice President, Worldwide Chairman, Pharmaceuticals and Joseph J. Wolk, Vice President, Investor Relations, will host the call (Press release, Johnson & Johnson, MAR 20, 2018, View Source [SID1234524910]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and other interested parties can access the webcast/conference call in the following ways:

The webcast and presentation material are accessible at Johnson & Johnson’s website www.investor.jnj.com. A replay of the webcast will be available approximately three hours after the conference call concludes.
By telephone: for both "listen-only" participants and those financial analysts who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is 877-869-3847. For participants outside the U.S., the dial-in number is 201-689-8261.
A replay of the conference call will be available until approximately 12:00 a.m. on April 25, 2018. The replay dial-in number for U.S. participants is 877-660-6853. For participants outside the U.S., the replay dial-in number is 201-612-7415. The replay conference ID number for all callers is 13677626.
The press release will be available at approximately 6:45 a.m. (Eastern Time) the morning of the conference call.

Affimed has filed a 20-F – Annual and transition report of foreign private issuers [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 20-F, Affimed, 2018, MAR 20, 2018, View Source [SID1234524903]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 20, 2018 OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies, reported that Dr. Jonathan Head, Chief Executive Officer at OncBioMune, will present a poster at the 2018 American Association for Cancer Research (AACR) (Free AACR Whitepaper) ("AACR") Annual Meeting taking place April 14 – 18, 2018 in Chicago, Illinois (Press release, Oncbiomune, MAR 20, 2018, View Source [SID1234524911]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The clinical trial abstract, entitled "Interim results of a phase 1a clinical trial of a PSA, IL-2, GM-CSF containing prostate cancer therapeutic vaccine in PSA defined biochemical recurrent prostate cancer patients," highlights the safety and efficacy of ProscaVax, the Company’s novel immunotherapeutic cancer vaccine, as evidenced through data collected in the study. Based upon the impressive body of data from the Phase 1a portion of the study, OncBioMune is forgoing the planned 1b portion and moving into two, separate Phase 2 studies of ProscaVax for late-stage and early-stage prostate cancer, respectively.

The abstract also will be published online in the 2018 Proceedings of the AACR (Free AACR Whitepaper).

Details of the abstract are as follows:

Session Title: Phase I Clinical Trials 2
Session Date and Time: Monday Apr 16, 2018 8:00 AM – 12:00 PM
Session Location: McCormick Place South, Hall A, Poster Section 42
Poster Board Number: 14

On March 20, 2018 Crescendo Biologics Limited (Crescendo), the drug developer of novel,targeted T-cell engaging therapeutics, reported Dr Brian McGuinness, Head of New Product andBusiness Development, Phil Bland-Ward (CSO) and James Legg (VP R&D) will be presenting a poster at AACR (Free AACR Whitepaper) (American Association for Cancer Research) Annual Meeting in Chicago, USA on 18 April 2018 (Press release, Crescendo Biologics, MAR 20, 2018, View Source [SID1234525091]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Crescendo team will be available to discuss the poster entitled "Multifunctional biologics fortargeted T-cell therapy based on in vivo matured fully human VH domains" within the "Antibodies,Fusion Proteins and Related Biologics session". This will cover the beneficial characteristics of Humabodies and their enhanced therapeutic potential over traditional monoclonal antibodies.

Poster details
Title: Multifunctional biologics for targeted T-cell therapy based on in vivo matured fully human VHdomains
Authors: J. Legg, B. McGuinness, P. Bland-Ward, P. Pack
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibodies, Fusion Proteins, and Related BiologicsSession Date and Time: Wednesday Apr 18, 2018 8:00 AM – 12:00 PM
Location: McCormick Place South, Exhibit Hall A, Poster Section 35

Poster Board Number: 11
Permanent Abstract Number: 5766

There will also be a poster by Eleven Biotherapeutics in the same session which includes data fromCrescendo. This poster, entitled ‘Engineering and characterization of anti-PSMA humabody-deBouganinfusion proteins’, will be at Board Number 15.

AACR’s Annual Meeting is being held in Chicago, Illinois from 14 – 18 April. The theme is ‘DrivingInnovative Cancer Science to Patient Care’. Presentations at the Annual Meeting will cover the latestbasic, translational, clinical, and prevention-focused research in the field, including important areas suchas early detection, cancer interception, and survivorship in all populations.

On March 20, 2018 RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases and cancer, reported that Mr. Guy Goldberg, RedHill’s Chief Business Officer, will present a corporate overview at the H.C. Wainwright Annual Global Life Sciences Conference, on Monday, April 9, 2018, at 11:05 am CET, at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco (Press release, RedHill Biopharma, MAR 20, 2018, View Source [SID1234524912]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio of the presentation will be available on the Company’s website at: View Source A copy of the presentation will be available on the Company’s website and a replay of the webcast will be available on the Company’s website for a period of 30 days.